The Neurological Biomarkers Market, estimated at USD 9.64 Bn in 2025, is expected to exhibit a CAGR of 13.3% and reach USD 23.12 Bn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
Market Dynamics:
Increasing incidences of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and others have boosted demand for neurological biomarkers for early diagnosis and treatment. It is estimated that around 50 million people globally are affected by Alzheimer's disease. With growing geriatric population, there has been increase in cases of neurological disorders, thus, boosting need for effective diagnosis through biomarkers. Rising R&D investments by pharmaceutical companies and research institutes for development of novel biomarkers can drive the market growth. Significant funds are granted for biomarker research to develop objective tools for accurate diagnosis, drug development and monitoring treatment response. This has prompted many biomarker companies to enter the market with innovative offerings.
Major Driver:
Increasing prevalence of neurological disorders
Rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other dementia can drive the global neurological biomarkers market growth. According to the Alzheimer's Association, an estimated 6.2 million Americans of all ages lived with Alzheimer's dementia in 2021. This number is projected to rise to around 13 million by 2050. Parkinson's disease affects over 10 million people worldwide, according to Parkinson's Foundation. With limited treatment options available, diagnosis of these disorders is crucial, and this boosts demand for reliable and accurate biomarkers. Neurological biomarkers help in early and accurate diagnosis which can allow doctors to start treatment sooner and monitor the effectiveness of therapies.
Advancements in biofluid analysis and brain imaging techniques
Continuous technological advancements in biofluid analysis techniques such as proteomics, metabolomics, and cerebrospinal fluid analysis as well as improvements in brain imaging methods including MRI, CT and PET scans have enabled discovery and validation of novel biomarkers. Biofluid analysis provides less invasive method for biomarker detection. Brain imaging techniques allow visualization of brain pathology progression. Integration of imaging and fluid biomarkers has enhanced detection of neurological changes associated with disorders. This has expanded clinical applications of biomarkers and is driving the market growth.
Lack of biomarker validation and standardization
One of the factors hampering the neurological biomarkers market is lack of validation and standardization of the discovered biomarkers. Currently, there is no validated and standardized biomarkers available for majority of neurological conditions. Biomarkers need to pass extensive validation studies to prove their reliability and reproducibility. The standard procedures and assay methods are required for consistent measurement of biomarker levels. This variability and lack of validation pose challenges to clinical adoption of biomarkers. Biomarker discovery is an expensive process and requires huge investments which deters many companies.